Loading institutional data...
Loading institutional data...
Insufficient data to determine institutional momentum.
Data as of Q3 2026
Loading snapshot...
Loading financials...
Loading valuation...
Loading analysis...
Loading dividends & returns...
Loading capital allocation...
Loading debt & leverage...
Loading performance...
Loading peer comparison...
Loading insider activity...
Loading ownership map...
Loading crowding analysis...
Loading conviction analysis...
Loading buy/sell flow...
Loading ownership trends...
Loading top holders...
Loading top holders...
Ranked against 38 sector peers with collected financials. Valuation from latest close × latest fiscal-year fundamentals; 13F conviction as of 2026-09-30.
Percentile is “goodness” within the peer set (100 = best). For valuation and leverage that means cheaper / less-levered ranks higher.
| Company | Mkt cap ▼ | P/E | EV/EBITDA | P/S | Rev gr | Gross | Net | ROE | ROIC | Net D/EBITDA | 13F |
|---|---|---|---|---|---|---|---|---|---|---|---|
| CVS | $115.5B | 65.0× | 11.6× | 0.3× | 7.8% | 45.0% | 0.4% | 2.4% | 2.4% | -0.9× | 656 |
| JD | $34.6B | 27.9× | 9.0× | 0.2× | 17.9% | 16.0% | 1.8% | 10.3% | 9.9% | -10.3× | 77 |
| ULTA | $27.9B | 25.3× | 15.0× | 2.3× | 9.7% | 39.1% | 9.3% | 41.1% | 40.3% | -0.2× | 291 |
| CPNG | $26.2B | 132.4× | 21.7× | 0.8× | 14.1% | 29.4% | 0.6% | 4.5% | 3.3% | -4.8× | 108 |
| CDW | $20.7B | 20.4× | 13.2× | 0.9× | 6.8% | 21.7% | 4.8% | 40.9% | 13.0% | 2.6× | 201 |
| W | $16.5B | — | 56.7× | 1.3× | 5.1% | 30.2% | -2.5% | 11.3% | -63.9% | 5.6× | 91 |
| DKS | $14.0B | 14.2× | 8.0× | 0.8× | 28.1% | 32.9% | 4.9% | 15.3% | 15.3% | -0.9× | 199 |
| CHWY | $8.4B | 40.1× | 19.6× | 0.7× | 6.2% | 29.8% | 1.8% | 44.7% | 44.7% | -2.2× | 130 |
| FCFS | $8.1B | 25.3× | — | 2.2× | 8.0% | 50.3% | 9.0% | 14.5% | 7.4% | — | 110 |
| VIPS | $6.1B | 1.3× | 2.6× | 0.4× | 2.0% | 23.1% | 6.8% | 17.7% | 15.5% | -1.8× | 45 |
| NSIT | $5.2B | 36.7× | 11.1× | 0.6× | -5.2% | 21.4% | 1.9% | 9.5% | 9.5% | -0.8× | 66 |
| BBWI | $4.6B | 7.3× | 5.5× | 0.6× | -0.2% | 43.7% | 8.9% | -50.7% | 24.9% | 2.1× | 91 |
| SIG | $4.6B | 16.8× | 6.8× | 0.7× | 1.6% | 39.5% | 4.3% | 15.0% | 15.0% | -1.6× | 65 |
| ASO | $3.7B | 10.9× | 6.1× | 0.6× | 2.0% | 34.8% | 6.2% | 17.4% | 14.2% | 0.2× | 73 |
| PTRN | $3.0B | — | 64.1× | 1.2× | 39.3% | 43.6% | 0.6% | 2.8% | 2.8% | -6.8× | 13 |
| GRDN | $2.6B | — | 26.3× | 1.8× | 17.9% | 20.2% | 3.4% | 22.6% | 22.6% | -0.7× | 19 |
| GCT | $2.2B | 16.9× | 11.6× | 1.7× | 11.1% | 23.3% | 10.6% | 28.3% | 28.3% | -2.5× | 41 |
| EZPW | $1.8B | 20.5× | 10.1× | 1.4× | 9.7% | 58.5% | 8.6% | 10.7% | 7.1% | 0.3× | 63 |
| SBH | $1.7B | 9.7× | 5.7× | 0.5× | -0.4% | 51.6% | 5.3% | 24.7% | 11.7% | 1.7× | 51 |
| RVLV | $1.6B | 26.9× | 17.1× | 1.3× | 8.5% | 53.5% | 5.0% | 12.0% | 12.0% | -3.7× | 31 |
| SVV | $1.4B | 67.6× | 10.2× | 0.9× | 9.2% | — | 1.3% | 5.2% | 2.0% | 3.1× | 24 |
| REAL | $1.4B | — | 135.6× | 2.0× | 15.4% | 74.6% | -6.0% | 10.1% | 10.1% | -16.7× | 31 |
| SPH | $1.2B | 11.0× | 8.6× | 0.8× | 7.9% | 60.6% | 7.4% | — | — | 4.3× | 31 |
| WINA | $1.0B | 25.4× | 18.3× | 11.9× | 5.9% | 96.4% | 48.4% | -77.6% | -77.6% | -0.2× | 37 |
| WOOF | $742M | 86.3× | 6.2× | 0.1× | -2.5% | 38.7% | 0.2% | 0.8% | 0.3% | 3.9× | 29 |
| YI | $26M | — | — | 0.0× | -9.0% | 5.8% | -0.2% | 3.2% | 4.4% | — | 1 |
Peers = companies sharing YI's sector (Retail-Drug Stores and Proprietary Stores) with collected SEC financials. Multiples use the most recent end-of-day close and latest fiscal-year fundamentals (trailing, not forward). Missing cells mean the peer never reported that line item, has no collected price, or has a non-positive denominator. Not investment advice.
Total shares institutions bought (green) vs sold (red) each quarter across all holders.
Inferred from quarter-over-quarter change in each fund's 13F position (new stakes count as buys, exits as sells). Not tick-level trades.
How management deployed cash over 8 years — and what it earned on reinvestment.
A reinvestment story — most cash went back into growth rather than to shareholders.
Reinvestment has been productive — operating income grew well per dollar put in. Current ROIC on all capital: 4%. Rough measure (includes maintenance capex).
Cash uses aggregated from the SEC cash-flow statement over 8 fiscal years. "Return on reinvestment" is a rough proxy — operating-income change ÷ cumulative CapEx + M&A — and includes maintenance capex. Educational — not a recommendation.
How much the company owes, how it's trended, and how comfortably it's serviced.
Green ≤ 1.5× · amber ≤ 3× · red > 3× (leverage relative to cash earnings).
Thin coverage — earnings barely cover interest. Effective rate ~19.0% on $26.8M of debt.
Cash of $73.1M fully covers short-term debt of $26.8M.
Mostly short-term debt (balance-sheet current vs non-current split). A year-by-year maturity schedule wasn't disclosed for this issuer.
Debt, cash, interest and equity from the SEC balance sheet & income statement. Effective rate = interest ÷ average debt. Educational — not a recommendation.
Top 1 institutional holders — bubble size is position value, color is the move since last quarter. Hover any holder for detail.
Drag any bubble to rearrange · size = dollar value of the position
What the company returns to shareholders — and whether it's covered by cash.
No dividend to cover. Last year: $0 dividends + $0 buybacks = $0 returned on $16.4M FCF.
Yields use the latest fiscal-year dividends/buybacks over current market cap. Dividends and buybacks from the SEC cash-flow statement; payout coverage vs net income and free cash flow. Educational — not a recommendation.
EOD close · as of 2026-10-29
How a revenue dollar becomes profit — FY2025
Dividends and buybacks are cash paid out, shown here against the same year's profit for scale — not funded from it.
Each value shows its share of revenue below it (common-size).
| Line Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $1.80B 100.0% | $14.40B 100.0% | $14.95B 100.0% | $13.52B 100.0% | $12.43B 100.0% | $8.20B 100.0% | $3.95B 100.0% | $1.79B 100.0% |
| Cost of Revenue | $1.69B 94.2% | $13.57B 94.2% | $14.10B 94.3% | $12.68B 93.8% | $11.80B 95.0% | $7.84B 95.5% | $3.79B 95.8% | $73.9M 4.1% |
| Gross Profit | $723.4M 40.3% | $829.2M 5.8% | $849.0M 5.7% | $840.0M 6.2% | $621.1M 5.0% | $365.8M 4.5% | $165.2M 4.2% | $104.3M 5.8% |
| Selling, General & Admin | $9.9M 0.6% | $70.9M 0.5% | $224.2M 1.5% | $205.6M 1.5% | $207.0M 1.7% | $128.2M 1.6% | $123.5M 3.1% | $98.8M 5.5% |
| Total Operating Expenses | $1.80B 100.0% | $14.40B 100.0% | $15.30B 102.3% | $13.89B 102.7% | $13.07B 105.2% | $8.68B 105.8% | $4.45B 112.5% | $2.19B 122.4% |
| Operating Income | -$340K -0.0% | $2.1M 0.0% | -$350.1M -2.3% | -$371.0M -2.7% | -$642.1M -5.2% | -$473.3M -5.8% | -$493.5M -12.5% | -$400.4M -22.4% |
| Interest Expense | $5.1M 0.3% | $28.3M 0.2% | $2.8M 0.0% | $13.4M 0.1% | $5.5M 0.0% | $8.8M 0.1% | $3.6M 0.1% | — |
| Interest & Investment Income | $556K 0.0% | $7.0M 0.0% | $8.8M 0.1% | $8.1M 0.1% | $9.8M 0.1% | $6.3M 0.1% | $4.8M 0.1% | $4.4M 0.2% |
| Other Income (Expense), net | $1.6M 0.1% | -$595K -0.0% | $7.6M 0.1% | $8.1M 0.1% | $14.9M 0.1% | $3.2M 0.0% | $834K 0.0% | $11.5M 0.6% |
| Pretax Income | -$3.2M -0.2% | -$20.7M -0.1% | -$353.2M -2.4% | -$376.1M -2.8% | -$621.0M -5.0% | -$467.1M -5.7% | -$501.8M -12.7% | -$382.0M -21.4% |
| Income Tax Expense | $2K 0.0% | $96K 0.0% | $251K 0.0% | $0 0.0% | $0 0.0% | $0 0.0% | $0 0.0% | $8K 0.0% |
| Net Income | -$3.2M -0.2% | -$20.8M -0.1% | -$353.4M -2.4% | -$376.1M -2.8% | -$621.0M -5.0% | -$467.1M -5.7% | -$501.8M -12.7% | -$382.0M -21.4% |
| Per Share | ||||||||
| EPS (Basic) | -$0.05 | -$0.38 | -$2.33 | -$2.50 | -$4.04 | -$2.77 | -$3.05 | — |
| EPS (Diluted) | -$0.05 | -$0.38 | -$2.33 | -$2.50 | -$4.04 | -$2.77 | -$3.05 | — |
| Weighted Avg Shares (Basic) | 174.0M | 171.8M | 168.6M | 166.6M | 165.9M | 164.8M | 163.7M | — |
| Weighted Avg Shares (Diluted) | 174.0M | 171.8M | 168.6M | 166.6M | 165.9M | 164.8M | 163.7M | — |
Source: SEC EDGAR XBRL filings (annual, fiscal year). Quarterly flow items are derived from cumulative filings; balance-sheet figures are as-of each period end. Ratios and margins are computed, not reported.
Solve the discounted cash flow backwards, then stress-test the assumptions.
Average free cash flow across the last 2 positive fiscal years (FY2024, FY2025). Smooths the cycle. Stock compensation is NOT charged — it is added back inside operating cash flow.
A reverse DCF cannot be solved for YI: its net cash ($46.2M) exceeds its market value, so enterprise value is negative. Discounting a positive cash-flow stream always gives a positive number, so no growth rate reaches that target. This is common for banks, brokers and payment companies, where customer balances sit in the cash line and are not the company's to spend.
On the basis ($23.1M) the requirement is off the scale. Shares issued to employees are added back in operating cash flow, so this basis treats them as free.
Default is 10.0% — this company's computed cost of capital, the same rate the Analysis tab discounts at.
2-stage DCF · 0.01B shares (market data) · net debt -$46.2M
Today's price is outside this grid at every discount rate shown — the assumptions it requires lie beyond the plotted range, which is itself the finding.
Reverse DCF: rather than guessing a fair value, we solve for the growth the current price implies, then you stress-test the assumptions. Enterprise value of the FCF stream, less net debt, ÷ shares. Educational — not a recommendation.
Last reported position per insider, carried forward. Steps can be a holding disclosed for the first time rather than a trade.
| Date | Insider | What it was | Shares | Price | Value |
|---|---|---|---|---|---|
| 2026-09-28 | 9 co-filers Group filing | Open-market sale | 38,120 | $0.18 | $7k |
| 2026-09-23 | 9 co-filers Group filing | Open-market sale1d late | 44,000 | $0.18 | $8k |
| 2026-09-23 | 8 co-filers Group filing | Open-market sale | 44,000 | $0.18 | $8k |
| 2026-06-15 | 9 co-filers Group filing |
Every row is classified by what it MEANT, not by its SEC code. A code is not a meaning: code P (“purchase”) also covers dividend reinvestment and employee stock purchase plans, and code S (“sale”) also covers 10b5-1 plan sales scheduled months earlier and option exercises sold the same day.
Across 30 days of all filings, $5.08bn of insider selling contained $3.50bn of plan sales and $0.46bn of exercise-and-sell. Only 29% was discretionary. Reading an unclassified feed badly overstates how much insiders decided.
Buys and sales are counted separately and never netted. They are different decisions by different people; a company where one officer bought while another sold is not “neutral”.
The holding line carries each insider's last reported position forward, so it shows the total held rather than a sawtooth of whoever traded that day. It covers only insiders who filed in the window.
“Filed late” counts calendar days past the two-business-day deadline with five days' grace, so a Thursday or Friday trade crossing a weekend is never flagged. It describes the company's filing discipline, not the trade.
Insider activity is descriptive. Nothing here is investment advice.
| Open-market sale101d late |
| 44,000 |
| $0.23 |
| $10k |
| 2026-06-15 | 8 co-filers Group filing | Open-market sale96d late | 44,000 | $0.23 | $10k |
| 2026-06-15 | 7 co-filers Group filing | Open-market sale | 44,000 | $0.23 | $10k |
| 2026-06-15 | 9 co-filers Group filing | Open-market sale | 58,800 | $0.23 | $14k |
| 2026-06-12 | 9 co-filers Group filing | Open-market sale104d late | 49,920 | $0.23 | $11k |
| 2026-06-12 | 8 co-filers Group filing | Open-market sale99d late | 49,920 | $0.23 | $11k |
| 2026-06-12 | 7 co-filers Group filing | Open-market sale | 49,920 | $0.23 | $11k |
| 2026-06-11 | 9 co-filers Group filing | Open-market sale | 111,100 | $0.23 | $26k |
| 2026-06-11 | 8 co-filers Group filing | Open-market sale | 111,100 | $0.23 | $26k |
| 2026-06-10 | 9 co-filers Group filing | Open-market sale1d late | 115,440 | $0.22 | $25k |
| 2026-06-10 | 8 co-filers Group filing | Open-market sale | 115,440 | $0.22 | $25k |
| 2026-06-10 | 7 co-filers Group filing | Open-market sale | 115,440 | $0.22 | $25k |
| 2026-06-09 | 9 co-filers Group filing | Open-market sale2d late | 12,000 | $0.23 | $3k |
| 2026-06-09 | 8 co-filers Group filing | Open-market sale | 12,000 | $0.23 | $3k |
| 2026-06-09 | 7 co-filers Group filing | Open-market sale | 12,000 | $0.23 | $3k |
| 2026-05-27 | 9 co-filers Group filing | Open-market sale120d late | 3,400 | $0.25 | $850 |
| 2026-05-27 | 8 co-filers Group filing | Open-market sale115d late | 3,400 | $0.25 | $850 |
| 2026-05-27 | 7 co-filers Group filing | Open-market sale15d late | 3,400 | $0.25 | $850 |
| 2026-05-27 | 9 co-filers Group filing | Open-market sale15d late | 70,440 | $0.25 | $18k |
| 2026-05-27 | 8 co-filers Group filing | Open-market sale11d late | 70,440 | $0.25 | $18k |
| 2026-05-27 | 7 co-filers Group filing | Open-market sale10d late | 70,440 | $0.25 | $18k |
| 2026-05-27 | 5 co-filers Group filing | Open-market sale | 70,440 | $0.25 | $18k |
| 2026-05-27 | 5 co-filers Group filing | Open-market sale | 70,440 | $0.25 | $18k |
| 2026-05-27 | 5 co-filers Group filing | Open-market sale | 3,400 | $0.25 | $850 |
| 2026-05-26 | 9 co-filers Group filing | Open-market sale121d late | 1,440 | $0.27 | $389 |
| 2026-05-26 | 8 co-filers Group filing | Open-market sale116d late | 1,440 | $0.27 | $389 |
| 2026-05-26 | 7 co-filers Group filing | Open-market sale16d late | 1,440 | $0.27 | $389 |
| 2026-05-26 | 9 co-filers Group filing | Open-market sale16d late | 29,280 | $0.27 | $8k |
| 2026-05-26 | 8 co-filers Group filing | Open-market sale12d late | 29,280 | $0.27 | $8k |
| 2026-05-26 | 7 co-filers Group filing | Open-market sale11d late | 29,280 | $0.27 | $8k |
| 2026-05-26 | 5 co-filers Group filing | Open-market sale | 29,280 | $0.27 | $8k |
| 2026-05-26 | 5 co-filers Group filing | Open-market sale | 29,280 | $0.27 | $8k |
| 2026-05-26 | 5 co-filers Group filing | Open-market sale | 1,440 | $0.27 | $389 |
| 2026-05-12 | 9 co-filers Group filing | Grant135d late | 413,168 | $0.00 | $0 |
| 2026-05-12 | 8 co-filers Group filing | Grant130d late | 413,168 | $0.00 | $0 |
| 2026-05-12 | 7 co-filers Group filing | Grant30d late | 413,168 | $0.00 | $0 |
| 2026-05-12 | 9 co-filers Group filing | Grant30d late | 413,168 | $0.00 | $0 |
Total return (dividends reinvested) vs the market, from quarter-end prices.
Above 0 = ahead of the S&P 500 since the window start; below 0 = behind. Rising means it's pulling ahead.
How far the stock fell below its prior peak. Deeper, longer drawdowns = a rougher ride to the same return.
Quarter-end, dividend-adjusted (total return). Beta & volatility from quarterly returns (annualized). Benchmark is the S&P 500 (SPY total return). Annual returns compound the quarters ending in each calendar year; the first and last years in a window may be partial. Past performance doesn't predict future results.
EOD close · as of 2026-10-29
Where each multiple sits in its own 8-yr range
Dot = today · shaded = middle 50% · line = median. Lower percentile = cheaper vs its own 8-yr history.
Is the profit real, and how strong is the balance sheet?
FY2025 · every deduction from revenue to net income
DuPont — the three levers
ROE 3% against ROIC 4% — -1% of the return on equity comes from leverage and buybacks rather than from the operating business.
What the company owes vs. what it holds
This shows debt/cash structure and net leverage. The year-by-year maturity schedule is on the Debt & Leverage tab.
Latest year: profit growth vs revenue growth
High operating leverage: profit moved 24.2× as fast as sales — great in an upturn, painful in a downturn.
Each line as % of revenue — the trend in color
| % of revenue | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|
| Cost of Revenue | 4.1 | 95.8 | 95.5 | 95.0 | 93.8 | 94.3 | 94.2 | 94.2 |
| Gross Profit | 5.8 | 4.2 | 4.5 | 5.0 | 6.2 | 5.7 | 5.8 | 40.3 |
| SG&A | 5.5 | 3.1 | 1.6 | 1.7 | 1.5 | 1.5 | 0.5 | 0.6 |
| Operating Income | -22.4 | -12.5 | -5.8 | -5.2 | -2.7 | -2.3 | 0.0 | -0.0 |
| Income Tax | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Net Income | -21.4 | -12.7 | -5.7 | -5.0 | -2.8 | -2.4 | -0.1 | -0.2 |
Green = margin-favorable vs the row's own range · red = unfavorable.
The metrics that matter, over time
A 30-second read on YI: price, valuation and headline fundamentals from SEC filings. The four questions at the top of the page are where the judgements live.
Cost of capital cannot be computed, so the spread is unknown.
| Fiscal year | Gross margin | Operating margin | Net margin |
|---|---|---|---|
| FY2018 | not reported | -22.4% | -21.4% |
| FY2019 | not reported | -12.5% | -12.7% |
| FY2020 | not reported | -5.8% | -5.7% |
| FY2021 | 5.0% | -5.2% | -5.0% |
| FY2022 | 6.2% | -2.7% | -2.8% |
| FY2023 | 5.7% | -2.3% | -2.4% |
| FY2024 | 5.8% | 0.0% | -0.1% |
| FY2025 | 5.8% | -0.0% | -0.2% |
No material counter-signal in the checked set: ROIC vs WACC spread, 5-year spread history, gross margin trend, operating margin trend, net margin against 3 years ago, revenue growth, ROIC ex-goodwill gap.
Missing from our data, so excluded from this answer: tax_rate.
Fewer than three profitable years with a cash flow statement, so cash conversion cannot be judged.
No material counter-signal in the checked set: FCF / net income over 3 and 5 years, Sloan accruals, SBC as a share of revenue, SBC as a share of operating cash flow, SBC-adjusted free cash flow, free cash flow per diluted share, buybacks against SBC issued, capex vs depreciation, free cash flow against revenue, share count since the first year on file, cash conversion cycle (DSO, DIO, DPO), receivables growth against revenue growth.
Missing from our data, so excluded from this answer: 3 years of cash flow.
Stressed coverage falls to -0.0x — below the level at which interest is reliably covered.
| EBITDA decline | Interest coverage |
|---|---|
| 0% | -0.07x |
| 5% | -0.06x |
| 10% | -0.06x |
| 15% | -0.06x |
| 20% | -0.05x |
| 25% | -0.05x |
| 30% | -0.05x |
| 35% | -0.04x |
| 40% | -0.04x |
| 45% | -0.04x |
| 50% | -0.03x |
| 55% | -0.03x |
| 60% | -0.03x |
Balance sheet at 2025-12-31. Undrawn revolving credit is not shown: the tag is collected but not yet mapped through to the API.
The maturity schedule is not part of this verdict — its filing anchor is often older than the balance sheet it sits beside, so a wall inside 24 months may not be visible here.
No growth rate within the range this model can express reaches the current price, so the requirement cannot be stated as a number.
No material counter-signal in the checked set: reverse-DCF implied growth, historical FCF CAGR, per-year FCF growth distribution, reporting-basis breaks, discount rate used, free-cash-flow basis (stock comp charged?).
Missing from our data, so excluded from this answer: implied_growth.